Athersys Inc ATHXQ

Healthcare Biotechnology

Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. The MultiStem clinical product is developed from a special class of stem cells called Multipotent Adult Progenitor Cells. The Company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).